STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIR-B) announces the intention of launching a voluntary share redemption program. “The successful market introduction of simeprevir has led to a very strong cash position and profitability for Medivir within a short time frame. Based on our strategy update and plan, which will be presented today at the Capital Markets Meeting, the company has analysed its capital structure and come to the conclusion that there is room for a larger capital distribution to the shareholders”, says Niklas Prager, CEO of Medivir.
Help employers find you! Check out all the jobs and post your resume.
